 Satravimab is a recombinant human monoclonal antibody that has been shown to prevent progression to hospitalization or death in non-hospitalized high-risk patients with mild to moderate coronavirus disease 2019 following either intravenous, IV, or intramuscular, EM, administration. Population pharmacokinetic, POP-PK, and exposure, response, ER, analyses were performed to characterize single-dose Satravimab pharmacokinetics, PK, and the relationship between exposure and response, probability of progression, as well as covariates that may contribute to between-participant variability in Satravimab PK and efficacy following IV or IM administration. Satravimab PK was described by a two-compartment model with linear elimination, absorption was characterized by a sigmoid absorption model. POP-PK covariate analysis led to the addition of the effect of body weight on systemic clearance and peripheral volume of distribution, sex on bioavailability and first-order absorption rate, KA, and body mass index on KA. This article was authored by Jennifer E. Sager, Asma El-Zaelic, Julie Passerelle, and others. We are article.tv, links in the description below.